Dr. Andriole has over 35 years of consistent contributions in the areas of benign prostatic hyperplasia, and prostate cancer screening and prevention research. He has contributed well over 400 peer-reviewed publications and serves on the editorial boards of several prestigious journals.

He is chairman of the prostate committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and principal investigator of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was chairman of the steering committee of the REDUCE Prostate Cancer Prevention Trial, as well as principal investigator of both the National Institute of Diabetes and Digestive and Kidney Diseases’ Medical Therapy of Prostatic Symptoms (MTOPS) BPH trial and the Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study.

Dr. Andriole is a member of the American Urological Association, the American Association for Cancer Research, the American Society of Clinical Oncology, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons, among other societies.